You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for New Drug Application (NDA): 204677


✉ Email this page to a colleague

« Back to Dashboard


NDA 204677 describes NEURACEQ, which is a drug marketed by Life Molecular and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the NEURACEQ profile page.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.
Summary for 204677
Tradename:NEURACEQ
Applicant:Life Molecular
Ingredient:florbetaben f-18
Patents:1
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 204677
Generic Entry Date for 204677*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 204677
Mechanism of ActionPositron Emitting Activity
Suppliers and Packaging for NDA: 204677
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677 NDA Life Molecular Imaging, Ltd 54828-001 54828-001-50 1 VIAL, MULTI-DOSE in 1 CONTAINER (54828-001-50) / 50 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength1.4-135mCi/ML
Approval Date:Mar 19, 2014TE:RLD:Yes
Patent:⤷  Try a TrialPatent Expiration:Mar 18, 2029Product Flag?YSubstance Flag?YDelist Request?
Patented Use:NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.